A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer ...

A previous trial involving patients with metastatic prostate cancer that was resistant to androgen pathway modulation (formerly referred to as castration-resistant) showed that adding talazoparib ...

CHICAGO -- Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, ...

Share on Pinterest A new trial is exploring an androgen receptor blocker in treating prostate cancer. FG Trade/Getty Images A second-generation androgen receptor blocker added to other prostate cancer ...

XTANDI is now the first and only novel hormone therapy available for the treatment of high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer in the European Union (EU) XTANDI ...

BERLIN -- Combining enzalutamide (Xtandi) with androgen deprivation therapy (ADT) significantly improved overall survival (OS) in patients with prostate cancer at high risk for biochemical recurrence, ...

MEDSIR, a leading international oncology research company, has presented the final results of the ZZ‑FIRST study during an ...

Talazoparib plus enzalutamide reduces progression risk by 50% in men with DNA repair alter ...

Please provide your email address to receive an email when new articles are posted on . Enzalutamide plus leuprolide and enzalutamide alone significantly extended MFS vs. leuprolide and placebo.

Adding enzalutamide (Xtandi) to androgen deprivation therapy (ADT) can extend metastasis-free survival while maintaining quality of life in men with prostate cancer who have a high risk for ...

The combination of enzalutamide with androgen deprivation therapy (ADT) significantly increases the chance of five-year survival for men with metastatic hormone-sensitive prostate cancer, according to ...